Everly Health vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 53)
Everly Health logo

Everly Health

ChallengerHealthcare

At-Home Diagnostics & Virtual Care Platform

Everly Health is a diagnostics-driven virtual healthcare company offering 35+ at-home lab test kits (Everlywell) and a telehealth platform connecting results to clinical care; raised $400M+; serves employers, health plans, and consumers;

AI VisibilityBeta
Overall Score
C53
Category Rank
#254 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
50
Perplexity
59
Gemini
57

About

Everly Health is an Austin, Texas-based health technology company founded in 2015 by Julia Cheek, operating at the intersection of consumer diagnostics and virtual healthcare through two integrated platforms: Everlywell, its direct-to-consumer at-home lab testing brand, and Everly Health Solutions, its B2B enterprise telehealth and diagnostics business. The company offers over 35 at-home test kits spanning metabolic health, thyroid function, food sensitivity, STI screening, fertility hormones, vitamins, and COVID-19 — enabling consumers to collect biospecimens at home and receive clinician-reviewed results through a CLIA-certified lab network with optional telehealth follow-up care. Everlywell tests are available direct-to-consumer online and through major retailers including Target and CVS.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

53
Overall Score
93
#254
Category Rank
#1
78
AI Consensus
80
stable
Trend
up
50
ChatGPT
94
59
Perplexity
89
57
Gemini
94
53
Claude
92
53
Grok
98

Key Details

Category
At-Home Diagnostics & Virtual Care Platform
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.